Pharmaceutical Executive Daily: FDA Approves Pimjetmi
From Pharmaceutical Executive · · 2 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.